Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to assess the corrected QT interval (QTc) effect of volanesorsen (ISIS 304801) administered as a 300 mg subcutaneous (SC) therapeutic and a 300 mg intravenous (IV; 2-hour infusion) supra-therapeutic dose relative to placebo in healthy adult male and female subjects.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02910635
Study type Interventional
Source Ionis Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1
Start date September 19, 2016
Completion date December 20, 2016

See also
  Status Clinical Trial Phase
Terminated NCT00593541 - Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging N/A